- Patients diagnosed as gastrointestinal stromal tumor (GIST) after disease progression
on or intolerance to imatinib mesylate, or advanced renal cell carcinoma (aRCC) will
be included in the study, or patients diagnosed as unresectable, well-differentiated
advanced and/or metastatic pancreatic neuroendocrine carcinoma.
- Any patient who does not agree that Pfizer and companies working with Pfizer use
his/her information will be excluded.
- Patients with hypersensitivity to sunitinib malate or to any other component of Sutent